“평택립카페👧 〔ØΡＤΑＬⓞ②ⓞㆍㄷΘм〕오피달리기 📒평택안마💂평택립카페💒평택스파🌎평택출장안마🐧평택아로마🐎평택스파🍂”的搜索结果，显示 311-320 项，共有 11969 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers. For the ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma. A ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 years after CAR-T. Survey questionnaires that have been previously validated in cancer populations will be used to assess: overall quality of life ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...